Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: A review of the literature

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 249-259

  Zaccara, Gaetano ^a   Specchio, Luigi M ^b  

^a Palagi Hospital   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Antiepileptic drugs; Epilepsy; Long term treatment; Review; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; ZONISAMIDE;

ADD ON THERAPY; AGITATION; ANOREXIA; APPETITE; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BEHAVIOR; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIPLOPIA; DISEASE ACTIVITY; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; EMOTIONAL DISORDER; EPILEPSY; FATIGUE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HOSTILITY; HUMAN; IRRITABILITY; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MONOTHERAPY; NAUSEA; NERVOUSNESS; NOTE; OBESITY; PROSPECTIVE STUDY; PSYCHOSIS; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SWEATING; THOUGHT DISORDER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT REDUCTION;

EID: 70449720669     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4063     Document Type: Note

References (48)

1. Baulac M. Introduction to zonisamide. Epilepsy Res. 2006;68 Suppl 2:S3-S9.
2. Rogawski MA, Lösher W. The neurobiology of antiepileptic drugs. Nature Rev Neuroscience. 2004;5:553-564.
3. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittel-Forschung. 1993;43:416-417. (Pubitemid 23112976)
4. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007;30:230-240. (Pubitemid 47356720)
5. Komatsu M, Hiramatsu M, Willmore LJ. Zonisamide reduces the increase in 8-hydroxyl-2-deoxyguanosine levels formed during iron-induced epileptogenesis in the brain of rats. Epilepsia. 2000;41:1091-1094. (Pubitemid 30692323)
6. Shah J, Shellenberger K, Canfax DM. Zonisamide. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors Antiepileptic drugs. 5th edition. Philadelphia: Lippincott, Williams and Wilkins; 2002. p. 873-879.
7. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20:593-597. (Pubitemid 28544284)
8. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008;4:493-506. (Pubitemid 351728521)
9. Sills GJ Brodie MJ. Pharmacokinetics and drug interactions with Zonisamide. Epilepsia 2007;48(3):435-441.
10. Wallace J, Shellenberger K, Groves L. Pharmacokinetics of zonisamide in young and elderly subjects. Epilepsia. 1998;39 Suppl 6:190-191.
11. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46(1):31-41. (Pubitemid 40179930)
12. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45(6):610-617.
13. Faught E, Ayala R, Montouris GG, Leppik IE; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774-1779. (Pubitemid 33096682)
14. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67-73. (Pubitemid 23152402)
15. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28:72-78. (Pubitemid 40471880)
16. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005;19(4):CD001416.
17. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand. 2006;114:157-168. (Pubitemid 44185908)
18. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley and Sons; 1981. p. 13-17.
19. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14:165-173. (Pubitemid 23064841)
20. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res. 2006;68S:S17-S24. (Pubitemid 43247593)
21. Wroe SJ, Yeates AB, Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand. 2008;118(2):87-93.
22. Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009;13(1):3-9.
23. Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study. Epilepsy Res. 2008;doi:10.1016/j.epilepsyres.2008.10.012.
24. Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia. 2006;47:1860-1864.
25. Newmark ME, Dubinsky S. Zonisamide monotherapy in a multi-group clinic. Seizure. 2004;13(4):223-225.
26. Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment:a postmarketing, multi-institutional survey. Seizure. 2004;13 Suppl 1:S34-S39. (Pubitemid 39420020)
27. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16:296-304. (Pubitemid 46614649)
28. Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res. 2006;68 Suppl 2:S11-S16. (Pubitemid 43247592)
29. Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localization-related epilepsies. Seizure. 2005;14(5):318-323. (Pubitemid 40916315)
30. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol. 2006;13(3):277-282.
31. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs: a meta-analysis of placebo-controlled studies. Seizure. 2008;17:405-421.
32. Berent S, Sackellares JC, Giordani B, Wagner JD, Donofrio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia. 1987;28:61-67. (Pubitemid 17231448)
33. Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav. 2008;12(1):102-108.
34. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23:17-73. (Pubitemid 47300374)
35. Ohtahara S, Yamatogi Y. Safety of zonisamide therapy. Prospective follow up survey. Seizure. 2004;13 Suppl 1:S50-S55. (Pubitemid 39420024)
36. Baulac M, Leppik IE. Efficacy and safety of agjunctive zonisamide therapy for refractory partial epilepsy. Seizure. 2007;75:75-83. (Pubitemid 47048652)
37. Thomas G, McCabe PH. Clinical use of zonisamide in generalsed seizure disorders. Epilepsia. 2005;46 Suppl 7:abstract 2.294.
38. Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized,double- blind study. Neurology. 2007;68(1):45-50.
39. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord. 2005;11(2):101-103. (Pubitemid 40279150)
40. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord. 2007;22(2):279-282. (Pubitemid 46374780)
41. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14):1820- 1825.
42. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67(12):1897-1906. (Pubitemid 46055195)
43. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226-1229.
44. Ghaemi SN, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowski MM. Is adjunctive open-label zonisamide effective for bipolar disorder? J Affect Disord. 2008;105(1-3):311-314. (Pubitemid 350245689)
45. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol. 2004;27(6):278-280.
46. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 2005;6(3):225-234. (Pubitemid 40975564)
47. Nuyen J, Schellevis FG, Satariano WA et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006;59:1274-1284. (Pubitemid 44708605)
48. Zaccara G. Neurological comorbidity and epilepsy: the implications for treatment. Acta Neurologica Scand. 2009. In press.